Abiopharma

🔍 Pershing Edward (Director)

Company: PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Sold 28,320 shares of 8% Unsecured Convertible Promissory Note at $2.862 per share (Derivative)
  Date: 2025-08-29 | Code: M | Expires: 2025-08-29 | Exercise: 2024-08-29 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3
• Acquired 283,200 shares of Series D-1 Convertible Preferred Stock (Derivative)
  Date: 2025-08-29 | Code: M | Exercise: 2025-08-29 | equity_swap_involved: 0 | shares_owned_after: 2,380,687.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
• F2: The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
• F3: The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2024 Note") at any time while the 2024 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2024 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2024 Note. The 2024 Note was issued pursuant to the Issuer's 2024 Financing.
• F4: On August 29, 2025, the 2024 Note was converted into 28,320 shares of Series D-1 Preferred Stock.